OXA (17-33)Potent and selective peptide OX1 agonist CAS# 343268-91-7 |
- RVX-208
Catalog No.:BCC4475
CAS No.:1044870-39-4
- GSK 525768A
Catalog No.:BCC1603
CAS No.:1260530-25-3
- Bromodomain Inhibitor, (+)-JQ1
Catalog No.:BCC1132
CAS No.:1268524-70-4
- (-)-JQ1
Catalog No.:BCC3603
CAS No.:1268524-71-5
- MS436
Catalog No.:BCC4037
CAS No.:1395084-25-9
Quality Control & MSDS
3D structure
Package In Stock
Number of papers citing our products
| Cas No. | 343268-91-7 | SDF | Download SDF |
| PubChem ID | 77846288 | Appearance | Powder |
| Formula | C79H125N23O22 | M.Wt | 1749 |
| Type of Compound | N/A | Storage | Desiccate at -20°C |
| Solubility | Soluble to 1 mg/ml in water | ||
| Sequence | YELLHGAGNHAAGILTL (Modification | ||
| SMILES | CCC(C)C(C(=O)NC(CC(C)C)C(=O)NC(C(C)O)C(=O)NC(CC(C)C)C(=O)N)NC(=O)CNC(=O)C(C)NC(=O)C(C)NC(=O)C(CC1=CN=CN1)NC(=O)C(CC(=O)N)NC(=O)CNC(=O)C(C)NC(=O)CNC(=O)C(CC2=CN=CN2)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCC(=O)O)NC(=O)C(CC3=CC=C(C=C3)O)N | ||
| Standard InChIKey | JPRBZUXULYLVPJ-HYNYKCRDSA-N | ||
| Standard InChI | InChI=1S/C79H125N23O22/c1-15-41(10)64(78(123)100-55(25-40(8)9)77(122)102-65(45(14)103)79(124)95-52(66(82)111)22-37(2)3)101-62(108)34-86-68(113)43(12)91-69(114)44(13)92-73(118)57(28-48-31-84-36-89-48)99-76(121)58(29-59(81)105)93-61(107)33-85-67(112)42(11)90-60(106)32-87-71(116)56(27-47-30-83-35-88-47)98-75(120)54(24-39(6)7)97-74(119)53(23-38(4)5)96-72(117)51(20-21-63(109)110)94-70(115)50(80)26-46-16-18-49(104)19-17-46/h16-19,30-31,35-45,50-58,64-65,103-104H,15,20-29,32-34,80H2,1-14H3,(H2,81,105)(H2,82,111)(H,83,88)(H,84,89)(H,85,112)(H,86,113)(H,87,116)(H,90,106)(H,91,114)(H,92,118)(H,93,107)(H,94,115)(H,95,124)(H,96,117)(H,97,119)(H,98,120)(H,99,121)(H,100,123)(H,101,108)(H,102,122)(H,109,110)/t41-,42-,43-,44-,45+,50-,51-,52-,53-,54-,55-,56-,57-,58-,64-,65-/m0/s1 | ||
| General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
| About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
| Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. | ||
| Description | Potent and selective peptide orexin OX1 receptor agonist (EC50 values are 8.29 and 187 nM for OX1 and OX2 receptors respectively). Truncated form of orexin A. |
OXA (17-33) Dilution Calculator
OXA (17-33) Molarity Calculator
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- TCS PrP Inhibitor 13
Catalog No.:BCC5999
CAS No.:34320-83-7
- Chelerythrine
Catalog No.:BCN5275
CAS No.:34316-15-9
- Boc-Abu-OH.DCHA
Catalog No.:BCC3200
CAS No.:27494-48-0
- 2,16-Kauranediol
Catalog No.:BCN5274
CAS No.:34302-37-9
- Harmine hydrochloride
Catalog No.:BCN2485
CAS No.:343-27-1
- 5,6-Dimethoxy-2-isopropenylbenzofuran
Catalog No.:BCN7195
CAS No.:34293-09-9
- 2,3-Dihydrohinokiflavone
Catalog No.:BCN6680
CAS No.:34292-87-0
- Chikusetsusaponin V methyl ester
Catalog No.:BCN3472
CAS No.:34291-22-0
- SDM25N hydrochloride
Catalog No.:BCC7054
CAS No.:342884-71-3
- Urotensin II-related peptide
Catalog No.:BCC5884
CAS No.:342878-90-4
- Gardneramine
Catalog No.:BCN5273
CAS No.:34274-91-4
- Angiotensin 1/2 (1-9)
Catalog No.:BCC1005
CAS No.:34273-12-6
- Benzyl 2,6-dimethoxybenzoate
Catalog No.:BCN3697
CAS No.:34328-54-6
- Cirsiliol
Catalog No.:BCN6822
CAS No.:34334-69-5
- NSC697923
Catalog No.:BCC4000
CAS No.:343351-67-7
- NS 3623
Catalog No.:BCC6190
CAS No.:343630-41-1
- Isoapetalic acid
Catalog No.:BCN5276
CAS No.:34366-34-2
- Ginsenoside Ro
Catalog No.:BCN5937
CAS No.:34367-04-9
- CP-673451
Catalog No.:BCC4981
CAS No.:343787-29-1
- Acebutolol HCl
Catalog No.:BCC4322
CAS No.:34381-68-5
- Isovallesiachotamine
Catalog No.:BCN3549
CAS No.:34384-71-9
- N-Demethyl-alpha-obscurine
Catalog No.:BCN7362
CAS No.:34399-44-5
- H-D-Pro-OH
Catalog No.:BCC3023
CAS No.:344-25-2
- Betamipron
Catalog No.:BCC8876
CAS No.:3440-28-6
(2E,25E)-11,14,17,33,36,39,42-Hepta-oxa-penta-cyclo-[41.4.0.0.0.0]hepta-tetra-con ta-1(43),2,5(10),6,8,18,20,22,25,27,29,31,44,46-tetra-decaene-4,24-dione.[Pubmed:21754440]
Acta Crystallogr Sect E Struct Rep Online. 2011 May 1;67(Pt 5):o1128-9.
The title compound, C(40)H(40)O(9), is a product of the double crotonic condensation of bis-(2-acetyl-phen-oxy)-3-oxapentane with bis-(2-formyl-phen-oxy)-3,6-dioxaoctane. The title macromolecule includes the 31-crown-7-ether skeletal unit and adopts a saddle-like conformation. The two ethyl-ene fragments have E configurations. The volume of the inter-nal cavity of the macrocycle is approximately 125 A(3). In the crystal, the mol-ecules are arranged at van der Waals distances.
Truncated Orexin Peptides: Structure-Activity Relationship Studies.[Pubmed:24707347]
ACS Med Chem Lett. 2013 Dec 12;4(12):1224-1227.
Orexin receptors are involved in many processes including energy homeostasis, wake/sleep cycle, metabolism and reward. Development of potent and selective ligands is an essential step for defining the mechanism(s) underlying such critical processes. The goal of this study was to further investigate the structure-activity relationships of these peptides and to identify truncated form of the orexin peptides active at OX1. Truncation studies have led to OXA (17-33) as the shortest active peptide known to date with a 23-fold selectivity for OX1 over OX2. Alanine, D-amino acid and proline scans have highlighted the particular importance of Tyr(17), Leu(20), Asn(25) and His(26) for agonist properties of OXA(17-33). The conformation of the C-terminus might also be a defining factor in agonist activity and selectivity of the orexin peptides for the OX1 receptor.
Structure-activity analysis of truncated orexin-A analogues at the orexin-1 receptor.[Pubmed:11266181]
Bioorg Med Chem Lett. 2001 Mar 12;11(5):737-40.
Truncated peptide analogues of orexin-A were prepared and their biological activity assesed at the orexin-1 receptor. Progressive N-terminal deletions identified the minimum C-terminal sequence required for maintaining a significant agonist effect, whilst an alanine scan and other pertinent substitutions identified key side-chain and stereochemical requirements for receptor activation.
